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Abstract
Background: The management of unruptured brain arteriovenous malformation (AVM) patients remains
controversial. Furthermore, curative attempts to treat ruptured AVM patients have not been questioned so far, and
there is a lack of prospective data on clinical results according to treatment modality. Endovascular treatment is
often used aiming to improve the safety or efficacy of surgery or radiation therapy, but benefits have never been
documented in a trial. A care trial context is needed to evaluate interventions at the same time they are practised.
Methods/Trial design: TOBAS is a pragmatic, prospective, multicenter, randomized, controlled trial and registry
which offers a care trial context for brain AVM patients, including surgical resection, radiosurgery or endovascular
embolization, alone or combined. The study includes two RCTs and a multimodality prospective registry. The
objectives of the proposed study are to assess whether preventive interventions (surgery, embolization, radiation
therapy, alone or combined), selected by the local treatment team and performed as locally practiced, randomly
allocated and compared with conservative management, in unruptured brain AVM patients eligible for active or
conservative management, can improve the proportion of patients having an independent outcome (modified
Rankin Scale (mRS) < 3, as assessed by a standardized questionnaire administered by non-masked care personnel) at
10 years. All patients judged ineligible for randomized allocation are to be entered in a multimodal registry. The
objective of a nested trial in patients with ruptured or unruptured AVMs to be treated by surgery or radiation
therapy, is to assess whether pre-surgical or pre-radiation embolization, randomly allocated and compared with no
embolization, can improve the proportion of patients with complete eradication of the AVM, as locally adjudicated,
combined with a good clinical outcome (mRS < 3). The study will require up to 2000 patients in approximately 30
centers or more, followed for 10 years. TOBAS is registered at clinicaltrials.gov: NCT02098252 as of 25 March 2014.
Keywords: Brain arteriovenous malformation, Randomized trial, Care trial, Ruptured AVM, Unruptured AVM,
Embolization, Radiosurgery, Neurosurgery
Background
Cerebral arteriovenous malformations (AVMs) are com-
plex, heterogeneous, uncommon lesions that can lead to
significant neurological disability or death, most com-
monly from intracranial hemorrhage (ICH) [1, 2]. Intra-
cranial AVMs are typically diagnosed before the age of
40, approximately 40–50 % with a hemorrhagic presen-
tation. An AVM-related seizure is reported as the pre-
senting feature in 20–35 % of cases and although these
can be successfully managed with anti-epileptic agents,
some AVMs lead to intractable seizures in spite of medi-
cation. Other presentations include headaches or focal
neurological deficits. AVMs can also be incidental find-
ings during investigation of unrelated symptoms.
Population-based data suggest that the annual incidence
of discovery of a symptomatic AVM is approximately 1
per 100,000 population [1–5].
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The management of brain AVMs is controversial and
complex. Three different modalities are currently used
(surgical resection; endovascular embolization; radio-
therapy) alone or in various combinations, depending on
local expertise, size, location of the lesion, and clinical
presentation. Over the last decade, there has been an
evolution of microsurgical as well as endovascular and
radiosurgical techniques to treat these lesions [6–13]. As
the management options have evolved, individual and
combined modality treatment protocols have developed
in various directions in different institutions. The choice
of management is largely dependent on the decisions of
the local physicians that make up the treatment team,
and a recent survey has demonstrated substantial vari-
ability in decision-making for almost all types of AVMs
[14]. Interventional therapies, when they are performed,
are assumed to decrease the risk of initial or subsequent
hemorrhage and, therefore, lead to better long-term out-
comes, an assumption that has yet to be proven, since
none of the treatment modalities or combinations
thereof has been shown to improve outcomes for brain
AVM patients. While microsurgical removal may pro-
vide a relatively safe and immediate cure for superficial
AVMs in non-eloquent brain, resection of malformations
in certain locations with a large nidus, deep draining
veins, or high-flow shunts may carry a relatively high
risk of morbidity [11, 13, 15–17]. Embolization can be
performed with curative intent for some AVMs with fa-
vorable angio-architecture. Recently, embolization with
Onyx has increasingly been proposed as a primary cura-
tive procedure [18–20]. This treatment modality is also
performed as an adjunct to other modalities, either to
render surgery technically simpler and possibly with less
morbidity, or to reduce the AVM size to make it more
conducive to cure with radiation therapy. The potential
benefits of pre-surgical embolization have never been
proven. Therapy may be initiated with a number of
embolization sessions, typically over a span of several
months. When endovascular treatment sessions have
not successfully obliterated the AVM, treatment may be
completed by radiation therapy, which takes 2–3 years
to occlude the AVM in up to 80 % of cases if the nidus
has been rendered relatively small (2 cm or less) [10]. As
with embolization, radiation therapy can also be per-
formed primarily with curative intent, particularly for
small, surgically inaccessible or less safely accessible le-
sions. The merits of endovascular treatment prior to ra-
diation therapy have been questioned, as the presence of
endovascular material has been purported to hinder the
obliteration of AVMs treated with radiation therapy, al-
though this too remains contentious [21–23].
Irrespective of initial treatment modality chosen, ther-
apy is sometimes suspended or interrupted because of a
complication (transient or permanent). The benefits of
pre-surgical or pre-radiation therapy embolization have
recently been questioned [10, 24]. Although the question
of which AVM treatment modality is the most appropri-
ate first choice remains controversial, consensus can be
reached in some circumstances. Surgical evacuation of a
life-threatening hematoma exerting significant mass
effect may remain uncontested, even though many pa-
tients with a hemorrhagic presentation do not necessar-
ily meet this threshold for surgical intervention. Almost
all other management choices remain debatable. A sys-
tematic review has proposed that approximately 7.1 % of
surgical candidates, 6.6 % of endovascular candidates,
and 5.1 % of radiosurgical candidates experience per-
manent neurological deficits after treatment, with out-
comes certainly influenced by case selection [13]. The
epidemiological study of Davies et al., using the Nation-
wide Inpatient Sample (NIS) data base and surrogates
such as location at discharge, compared outcomes fol-
lowing AVM treatment with the different modalities,
and found the worst outcomes were obtained when
endovascular treatment was combined with surgical
management, for both ruptured and unruptured AVMs
[7]. All current therapeutic options involve substantial
risks of mortality and morbidity (ranging from 1–30 %;
reviewed in [10, 11, 13]) and benefits have never been
shown in randomized trials. For decades the manage-
ment of brain AVMs has been based on a comparison
between the risks of conservative management, or the
so-called natural history of the disease (the risks of rup-
ture according to various characteristics of a particular
lesion in a particular patient) and the risks of treatments
judged to be most appropriate for each patient. Al-
though this rationale makes intuitive sense, it is based
on assumptions that have never been validated and on
extrapolations of data from error-prone observational
studies over the lifetime of patients with AVMs [25].
The natural history studies indicate an overall risk of
initial hemorrhage of approximately 1–4 % per year, al-
though the long-term consequences in terms of the
probability of death or long-term disability following
ICH remain unclear [26–31]. Mortality from the first
hemorrhage has been reported to occur between 10–
30 % of patients with a ruptured AVM, but some recent
data suggest that the mortality rate may be lower, and
perhaps only 10–20 % of survivors have long-term
disability [27, 30]. Hemorrhagic presentation is con-
sidered the most reliable risk factor for a repeat
hemorrhage [26, 27, 29]. Other risk factors, such as
deep venous drainage, are less consistently identified,
and typically may entail not only a higher risk of rup-
ture without treatment, but also a higher risk of treat-
ment. Thus, the first distinction to be made regarding
AVM patients is whether or not they present with
ICH. Because ruptured brain AVMs presumably have
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a higher hemorrhage risk (4.5–34 %) than unruptured
ones (0.9 –8 %) [32], interventional treatment is per-
haps advisable [2, 17, 33] at least in some patients,
despite the absence of evidence from randomized
controlled trials (RCTs) that the benefits outweigh the
risks [6]. More controversial is the management of
unruptured brain AVMs.
Recently, the results of A Randomized Trial of
Unruptured Brain AVMs (ARUBA), the only RCT on
AVMs, were published [34]. This ambitious trial
sought to compare the outcomes of patients with
unruptured AVMs following random allocation of
treatment versus conservative management strategies.
Patients were included only if they had no prior his-
tory or imaging evidence of a previous hemorrhage.
The original study plan was to randomize 800 pa-
tients and examine the primary outcome, a composite
measure of stroke and death (from any cause). The
design was later revised to accommodate low recruit-
ment rates [34]. Interventional management, when al-
located, was decided locally by the care team and
included endovascular, surgical, and/or radiation ther-
apy, alone or in combination. The study was stopped
by the Data Safety Monitoring Board (DSMB) after
6 years, and after enrollment of 223 patients who had
been followed a mean of 33 months. The primary
outcome was observed in 11 patients randomized to
medical management (10 %) and 33 patients random-
ized to interventional therapy (29 %). Whether or not
this disparity in outcome will persist as the study
continues remains to be seen. The results confirm
previous data with a 2.2 % (95 % CI 0 · 9–4 · 5) annu-
alized hemorrhage risk for patients followed up with-
out interventional therapy. Although ARUBA does
offer the most reliable information on unruptured
AVMs so far, the study has been criticized in many
ways [35–38]: recruitment was meagre, with approxi-
mately one patient per year per center; generalizability
of results has been questioned, given the small total
number of patients and the small proportion of
screened patients that were actually included in the
study (226/1740 or 13 %) [25]. Only five patients
were allocated to neurosurgery alone (12 combined
with embolization), even though 76 (65 %) of the pa-
tients in the treated group were Spetzler-Martin (SM)
grade I or II, which are cases typically managed with
surgical resection alone, the modality considered to
be the “gold standard” for these lesions in many cen-
ters, particularly in North America. For a disease with
a long natural history, a mean follow-up of 33 months
(SD 19 · 7) has been considered too short to support
the potential benefits of curative treatments or to
meaningfully compare events. The short follow-up fa-
vours the medical management group because all risk
is accepted early with interventional therapy. Finally,
the primary endpoint of stroke or death, with “stroke”
defined as “any new focal neurologic deficit, seizure,
or new onset headache associated with imaging find-
ings of hemorrhage or infarction” may have included
too many minor or transient events, considering that
curative treatment aims to reduce lifetime risks of
life-threatening or debilitating hemorrhages [36]. Be-
cause of the small total number of patients, hetero-
geneity of the population, and non-standardized
management choices, the role for curative treatments
of unruptured brain AVMs may remain uncertain,
even once the long-term results of ARUBA become
available. In the meantime, in the presence of such
uncertainty, some authors have declared invasive
curative treatments to be “experimental therapy” [39].
A recent observational study of Scottish cohorts
followed for 12 years, reporting statistics similar to
ARUBA, concluded that conservative management of
unruptured AVMs was superior [40]. Although no
clinical trial data exist on the effect of interventional
therapy even after AVM hemorrhage, the most con-
tentious issue at present is whether interventional
therapy should be offered to patients with unruptured
AVMs. In such patients, the best management strat-
egy remains unknown, but the burden of proof is on
those offering the potentially risky preventive inter-
ventions. In such a context, interventions may be best
proposed in the context of a care trial [41]. TOBAS
(Treatment of Brain Arteriovenous Malformations
Study) is a study that addresses this crucial question
of conservative versus interventional management for
AVMs judged appropriate for either management
paradigm.
The next important problem addressed by TOBAS
is the role of adjunct embolization in patients with
ruptured or unruptured AVMs treated with surgery or ra-
diosurgery. Although endovascular AVM embolization
can occasionally eradicate lesions before surgery or radi-
ation therapy [20], and although embolization may poten-
tially improve the safety and efficacy of surgical or
radiosurgical treatments, it remains contentious whether
it is worthwhile to accept the additional risks of endovas-
cular treatment for a greater overall benefit for patients
with brain AVMs that are treatable by surgery or ra-
diation therapy alone. It is possible that the overall
morbidity and mortality of the combined interven-
tional management strategy is increased when
embolization is added to a surgical or radiosurgical
procedure [24, 42]. Therefore, pre-surgical or pre-
radiosurgical embolization can be offered, but given
such uncertainty, it may be best offered only as a
randomized allocation between embolization or no
embolization, within the context of a proper trial.
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This second randomized allocation has, therefore,
been nested within TOBAS.
Objectives
The general objective of the TOBAS trial is to offer a
care trial context for the management of patients with
brain AVMs (ruptured or unruptured) [41].
The primary objective of the first randomized study is
to compare the effect of conservative versus interven-
tional management (i.e. neurosurgery, radiosurgery,
embolization, alone or combined) on a composite of dis-
abling stroke or death from any cause at 10 years in pa-
tients with unruptured AVMs (patients with ruptured
AVMs will be analyzed separately in secondary analyses).
The primary objective of the second randomized study
is to compare the effects of embolization prior to neuro-
surgery or radiotherapy versus neurosurgery or radio-
therapy alone, in the management of patients with
ruptured or unruptured AVMs, on a composite outcome
of complete obliteration of the AVM combined with an




TOBAS is a prospective study that includes 2 multicen-
ter pragmatic 2-arm parallel group RCTs using a 1:1 ra-
tio and a clinical registry of patients managed outside
the RCTs. The complete protocol is available at www.cli-
nical-care-trials.org.
Patients
All patients with an AVM diagnosed at a participating
clinical center will be candidates for the study. Patients
with unruptured AVMs considered for curative treat-
ment, without contraindication to intervention, will be
candidates for the randomized allocation of management
between interventional and conservative management.
All patients judged by the multidisciplinary team as
potential beneficiaries from endovascular therapy as
pre-surgical or pre-radiosurgical treatment will also
be candidates for the nested randomized study on
pre-embolization. The nested study is a randomization be-
tween embolization or no embolization for patients allo-
cated to or being prescribed surgery or radiation therapy
(when treatment is judged possible with or without
embolization). Patients may be referred for enrollment by
their clinical neurologist, neurosurgeon, or interventional
radiologist.
Participating centers
Participating centers are expert referral centers that can
provide multidisciplinary and multimodality care for
brain AVMs. There is no requirement for a minimal
number of procedures (per center or per surgeon per
year) but the experience of centers will be recorded.
Eligibility criteria
TOBAS is a pragmatic care trial [41]. Any patient with a
brain AVM can be included in the randomized trial or
registry portion of the study.
Study interventions
All patients participating in the trial will receive “stand-
ard medical care,” including stroke risk factor reduction
(smoking, hypertension, diabetes, hyperlipidemia) as
routinely, locally performed, irrespective of treatment
allocation.
Medical management
Patients allocated to the medical management arm will
receive no additional interventional treatment.
Interventional therapy
A patient allocated to interventional therapy is expected
to begin interventional therapy within 3 months follow-
ing randomization. Interventional therapy consists of ei-
ther endovascular attempts to occlude the nidus and
feeding vessels, microsurgery for resecting the AVM it-
self, or radiosurgery, alone or in combination, and with
the various locally recommended timing of each treat-
ment session. Interventions are applied flexibly, as in
normal practice, and there is no standardization required
per protocol.
Endovascular treatment may include AVM embolization,
or even coiling of aneurysms in the vascular territories
feeding the AVM (AVM-related aneurysm). The
embolization materials used for those who undergo
embolization as part of the treatment plan will be limited
to those agents approved by the Food and Drug Adminis-
tration (FDA) or by the approval agency applicable to the
country in which the patient receives treatment at the time
of the procedure. This plan allows for the introduction of
new agents during the course of the study. The name of
the agent and the frequency of use will be recorded on the
Interventional Therapy Form.
Microsurgery may include AVM resection, and
aneurysm clipping related to AVM. The operating time
and the necessity of transfusions will be recorded on the
Interventional Therapy Form.
Radiotherapy involves the targeting of the AVM nidus
and adjacent vessels intended to induce a reduction in
AVM size, and possible obliteration, of the AVM. Based
on local patterns of practice, variations exist in the type
of equipment used, the methods of measurement used
to assess the location and size of the AVM chosen for
therapy, the individual doses and numbers of treatments,
and whether radiosurgery is used before or after
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embolization or microsurgery. The modality, energy,
number of isocenters, collimator size, prescription and
duration of treatment will be recorded on the Interven-
tional Therapy Form.
The goal of the interventional therapy is to achieve
eradication of the AVM. The eradication plan may in-
clude any or a combination of endovascular, surgical, or
radiotherapy treatments. Following interventional ther-
apy, using a diagnostically relevant imaging study, treat-
ment outcome will be documented as: complete AVM
removal or occlusion, or incomplete AVM removal or
occlusion.
Outcomes
The primary outcome of the first RCT and of the regis-
try is a composite of disabling stroke (resulting in modi-
fied Rankin Scale (mRS) > 2) or death from any cause at
10 years. Functional outcome status will be measured by
the modified Rankin Scale, the most widely used out-
come measure for stroke [43], using a standardized
questionnaire administered by unblinded care personnel.
Secondary outcomes include overall mortality (all
causes), overall morbidity (mRS > 2; all causes) at 1, 5
and 10 years, the occurrence of any neurological event
during follow-up, the incidence of permanent (more
than 3 months) disabling (mRS > 2) peri-operative
(within 31 days) complications, the incidence of any
peri-operative (within 31 days) complication, the inci-
dence and number of hospital admissions, peri-
treatment hospitalization lasting more than 15 days,
discharge to a location other than home, occurrence of
an ICH after enrollment and for up to 10 years, and oc-
currence of failure to eradicate the AVM (as determined
by angiography) using the intended treatment modality.
The primary outcome of the nested RCT on pre-
surgical or pre-radiation embolization is complete oblit-
eration of the AVM (judged by local angiographers)
combined with an independent functional outcome
(mRS < 3; using a standardized questionnaire adminis-
tered by unblinded care personnel) at the end of the
management plan (no less than 3 months after the last
procedure; no more than 3 years after radiation therapy).
Number of patients
The number of patients to be recruited depends on the
specific trial hypotheses:
i) Randomized comparison of interventional treatment
and conservative management:
Interventional management of unruptured brain
AVMs suitable to both conservative and curative treat-
ment alternatives will lead to a decrease in the number
of poor outcomes (defined as mRS >2) from 25 to 15 %
at 10 years.
i) Nested trial on the role of embolization in the
treatment of brain AVMs:
Pre-surgical or pre-radiosurgery embolization of cere-
bral AVMs can decrease the number of treatment fail-
ures (failure to achieve: (angiographic cure with good
outcome)) from 20 % to 10 %.
ii) Secondary hypotheses:
 Curative treatment of cerebral AVMs can be
accomplished with an acceptable up-front risk,
defined as the occurrence of a treatment-related
permanent disabling neurological complication in
10 to 20 % of patients or less (depending on
AVM grade).
 Embolization of cerebral AVMs treatable by
surgery or radiosurgery alone can be
accomplished with an acceptable risk, defined as
permanent disabling neurological complications
of 8 % (3.4 to 12.6 %, 95 % CI).
Approximately 540 randomized patients (270 per
group) are necessary to detect a hypothesized reduction
of 10 % (from 25 to 15 %) in poor outcomes at 10 years,
between interventional and conservative groups (all mo-
dalities included). It is too early to estimate the number
of cross-overs that will occur; with a long follow-up
period, losses can be substantial; analyses using the
intention-to-treat principle would require a larger num-
ber, according to the proportion of cross-overs and
losses to follow-up.
In theory, each management strategy should be separ-
ately validated, which would mean that for each modal-
ity, we would eventually need to recruit 540 patients or
more.
For the nested study on pre-therapeutic embolization,
440 patients (220 per group) will be required to detect
the hypothesized 10 % increase (from 80 to 90 %) in rate
of success, defined as complete AVM eradication with-
out the occurrence of a disabling complication.
Randomization and allocation of treatment options
Patients will be allocated a management option accord-
ing to a combination of clinical judgment and
randomization, as shown in Fig. 1. Patients for whom
interventional management is not indicated will be pro-
posed for conservative management and entered in the
registry. Patients presenting with unruptured AVMs
(and no other formal indication or contraindication for
therapy) and considered for definitive therapy will be
allocated interventional treatment or conservative
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management by randomization (ratio 1:1). The treat-
ment modality to be used in the case of interventional
management will be predefined according to clinical
judgment prior to randomized allocation stratified ac-
cording to treatment modality.
Some patients with difficult but ruptured AVMs, or
patients that have presented with rupture in the past,
but who remain untreated, may also be offered ran-
domized allocation if the treating team judges that
they are eligible for both management options.
The interventional therapy arm of the trial involves
a plan for eradication of the AVM using: 1) surgical
resection when the lesion is considered by a multidis-
ciplinary team to be safely “operable,” or; 2) radiation
therapy when the AVM is smaller than 3 cm, and
considered to not be safely “operable,” or; 3) curative
embolization, when the lesion is considered curable
by embolization (with or without adjunct treatments
when embolization turns out to be incomplete). Any
treatment modality, if judged by the team to be
appropriate, can potentially be combined with endo-
vascular embolization.
Patients with AVMs that the multidisciplinary team
expects might benefit from endovascular treatment prior
to surgical resection or radiation therapy will be pre-
randomly allocated to embolization or to no
embolization, provided that treatment without adjunct
embolization is also felt to be possible.
The patient is registered via a web-based system
(http://www.medscinet.com/tobas) that will structure
the forgoing allocation process and immediately com-
municate the result of the randomization (when appro-
priate) to the multidisciplinary team. The web-based
platform is available 24 hours a day and assures conceal-
ment of the sequence until interventions are assigned.
The first randomization will be stratified according to
intended primary interventional management groups (sur-
gery, radiation therapy, or embolization). A minimization
algorithm will be used to ensure balance between groups
with respect to: 1) presentation (hemorrhagic (Group I)
Fig. 1 Treatment allocation. The figure illustrates the list of questions (a-d) used by the multidisciplinary team to allocate treatments by clinical
judgment (a-b) and/or randomization (c-d)
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versus all other presentations (Group II)); 2) according to
SM AVM grade (I–II versus III–V). After the patient has
been pre-randomized and placed in the appropriate arm of
the study, the treatment team will verify that the intended
management course is appropriate and considered optimal
care for the patient. The patient will then be presented the
recommendations of the multidisciplinary team (including
the allocation by randomization when appropriate) and will
be offered participation. There will be full disclosure of
the pre-randomized nature of the study (Zelen’s design
[44, 45]) to the patients, when this procedure will be used.
They will then be asked to sign the consent form. Patients
not willing to comply with the proposed allocation will
still be offered participation in the study, but a cross-over
will be recorded. Patients treated according to clinical
judgment alone will be entered in the registry portion of
the study (after the consent form is signed).
Justification of stratification, minimization criteria and
other design choices such as Zelen’s are provided in
Additional file 1.
Planned patient follow-up and data collection
All patients will be seen in clinic 6–8 weeks after treat-
ments, at 6 months, 1 year, and yearly thereafter, as part
of routine follow-up care. These intervals will serve to
determine mRS scores, and to inquire about possible
neurological events and hospital admissions. Patients
treated by embolization or surgery are typically followed
up with catheter angiography 3 months after the last
treatment session, to prove definite eradication of the le-
sion. Patients treated by radiosurgery are typically
followed up by yearly magnetic resonance angiogram
(MRA) and catheter angiography 2–3 years after irradi-
ation. Patients managed conservatively are typically
followed-up by MRA at yearly intervals, with the interval
to non-invasive imaging increasing with time and
demonstrated stability. Thus all patients will have inva-
sive or non-invasive imaging (computed tomography
angiogram (CTA) or MRA) 3 months to 3 years post-
treatment (depending on treatment modality) to deter-
mine the presence of a residual nidus. This follow-up is
considered to be standard of care. A minimal follow-up
imaging program, in treated or untreated patients,
should include MRI and MRA at 1, 5 and 10 years. We
have minimized the number of tests and visits for pa-
tients. The case report forms (CRFs) can be filled at the
time of standard clinical visits. There is no extra test,
risk or cost beyond what is considered normal care
(Table 1).
Statistics
There are many components to this study (Table 2). It is
important to distinguish the two randomized levels,
which will be analyzed separately as randomized trials
(intention-to-treat and per-protocol), and the registry
portion, analyzed as an observational study.
Descriptive tables on demographic variables and po-
tential risk factors will be provided to describe the
groups at baseline. Continuous variables will be summa-
rized in tables and will include the number of subjects,
means, standard deviations, medians, minima and max-
ima. Categorical variables will be presented in tables as
frequencies and percentages.
For the first RCT (interventional or conservative man-
agement strategy), the primary analysis, concerning the
primary outcome (mRS > 2 or death from any cause at
10 years) of unruptured AVM patients will be analyzed
using a Fisher’s exact test and the odds ratio with 95 %
confidence interval will be reported. The same analysis
will be performed for the ruptured group (considered a
secondary analysis). All other secondary objectives and
Table 1 Schedule of evaluation
Evaluation Screening Pre-entry Entry Treatment Discharge 6 months and yearly 10 years
Documentation of AVM X
Imaginga X X X
Informed consent X
Medical treatment/history X
Clinical assessment X X X
Neurological exam X X X
Failure to occlude AVM X
Number of days in hospital X
Discharge disposition X
Residual nidus X X
Hemorrhage during FU X X
aIncluding catheter or non-invasive angiography and brain magnetic resonance imaging (MRI) imaging whenever clinically indicated
AVM arteriovenous malformation, FU follow-up
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analyses for this first RCT will be analyzed in the same
way.
The primary outcome of the second RCT (complete
obliteration of the AVM combined with a mRS < 3; pre-
surgical or pre-radiation embolization versus no
embolization) will be analyzed with a logistic regression
adjusted for ruptured status and intervention. Adjusted
odds ratio and 95 % confidence interval will be reported.
Moreover, stratified results by ruptured status and inter-
vention will be presented.
The patients entered in the registry will be included in
secondary analyses designed to estimate treatment mor-
bidity for each modality and natural history of untreated
patients, just as an observational study, for unruptured
and ruptured AVMs, for high-grade and low-grade le-
sions. There are four groups and eight registered sub-
groups (Table II). Predetermined subgroups that will be
examined include: 1) according to treatment modality;
2) according to presentation (hemorrhagic versus all
other presentations) and 3) according to SM AVM grade
(I–II versus III–V). With a 10-year follow-up, it is likely
that there will be losses to follow-up, but it is too early
to estimate how many. Primary analyses will include
three categories (good outcome; bad outcome; lost to
follow-up). We will explore results when a best case sce-
nario (patients lost to follow-up have a good outcome)
and a worst case scenario (they have a bad outcome) are
imputed.
All analyses will be done with SAS software (SAS Insti-
tute Inc., Cary, NC, USA) using a significance level of 5 %.
Trial monitoring
Monitoring of trial data quality will be web-based and
performed by periodic reviews of data stored in the data-
base. Blinded data will be prepared for periodic safety re-
views at pre-specified intervals by an independent Data
Safety and Monitoring Committee (DSMC) to ensure
patient safety. Serious adverse events will be tabulated
for the registry and randomized trial sections of the
study, separate or aggregated, a) per management group
(interventional or conservative), b) per treatment group
(observation, surgery, embolization, radiation therapy)
and c) according to minimization criteria (ruptured or
unruptured; SM I–II or more). More specifically, the
DSMC will ensure that treatment-related complications
are within the confidence intervals compatible with the
study hypotheses. The DSMC will also monitor the
number of cross-overs as the study progress, to adjust
the hypotheses or change the design. The DSMC will be
composed of benevolent physicians (at least one neuro-
surgeon, one radiologist, one neurologist) not involved
in the conduct of the trial, as well as a statistician and
an ethicist. A DSMC charter predefined all trial monitor-
ing procedures. Unblinding criteria will be pre-specified
in the DSMC charter.
Ethics approval
The Institutional Review Board (CER) of the Centre Hos-
pitalier de l’Université de Montréal (CHUM) approved
the protocol on 22 October 2013 (Study ID: 13.315).
Secondary approval will be obtained from all local ethics
committees. Recruitment will not begin in any individual
center until all local ethical approvals have been ob-
tained. Based on the Declaration of Helsinki, written in-
formed consent will be obtained from each participating
patient or appropriate surrogate in oral and written form
prior to enrollment.
Discussion
One of the difficulties that has delayed the design of tri-
als on AVMs is the relatively small number of heteroge-
neous patients treated by multiple treatment modalities,
which renders well-powered randomized studies ad-
dressing specific questions on each treatment option dif-
ficult to conceive. To mitigate this difficulty, we have
chosen to design a single trial and registry and keep
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inclusion criteria as broad as possible. The reason is that
the most urgent necessity is to provide patients with a
randomized trial context within which promising but
unvalidated care can be provided in a large collaborative
effort. This choice of study design has two correlates:
the first is that as currently conceived TOBAS raises a
general question as to whether unruptured AVMs
should be treated. Although the number of patients for
whom the uncertainty is present may be quite large, rea-
sons are multiple and varied. For many clinicians these
are as many, distinct research questions regarding what
are considered heterogeneous groups of patients or le-
sions that should not be lumped together into an overall
outcome result, for fear of averaging results that would
have pulled in opposite directions. We must, however,
remember the first goal of care trials: to protect present
patients from unjustified beliefs and hypotheses, and
offer optimal care in the presence of uncertainty [41].
From an organizational perspective, it is easier to
propose a single inclusive large trial than to multiply
small trials with narrow selection criteria. TOBAS could
be split into five different trials or more. Given the diffi-
culties with recruitment that were previously encoun-
tered in ARUBA, it is difficult to predict which ‘trial’
would recruit. It is possible, however, to pre-specify sub-
groups that will be individually monitored by the DSMC.
Thus, the second implication of our design choice is that
the DSMC must regularly be provided with subgroup-
specific safety data to ensure that an emerging obvious
discrepancy in clinical outcome will be addressed in a
timely manner in order to prevent additional patient
morbidity. We will then be in a position to identify
which treatment modality and which patients should be
submitted to randomized allocation as the trial pro-
gresses. Because each treatment modality should eventu-
ally be validated as beneficial before it becomes accepted
as standard care, we may have to adjust hypotheses and
the number of recruited patients as the trial proceeds, to
eventually come up with answers that can apply in clin-
ical practice.
We have previously been confronted with the difficul-
ties involved in recruiting patients in trials comparing
invasive treatments and conservative management [46]).
In this particular case, difficulties are multiplied by the
number of possible treatment modalities, in isolation or
combined, and by the fact that not all options are pos-
sible for a particular patient. Thus, allocation of treat-
ments is a combination of clinical judgment and
randomization. We believe pre-randomization is particu-
larly suited to this context [44, 45]. For each patient, it
will clearly be explained which portion of the eventually
recommended treatment plan was decided using the
clinical judgement of the expert team, and which part of
the treatment plan was randomly allocated.
The neurovascular community has recently voiced dis-
content regarding the way clinical trials have been designed
and conducted in the past decade [47, 48]. While some
criticisms may be unfair, the general feeling is that trials
are slow, rigid, costly, heavy duty machineries that eventu-
ally recruit only a small proportion of patients being
treated with the target interventions, eventually providing
results that cannot apply to clinical practice. We must
proceed with fundamentally different sorts of trials [49].
Physicians involved in the treatment of brain AVMs
believe that interventional treatments are indicated to
prevent the lifetime risks of rupture or re-rupture and
resulting poor outcomes. Unfortunately, the benefits of
treatment have never been proven in a RCT, and any
treatment entails immediate risks. Although all treat-
ment modalities have been performed in expert centers
for decades, it is difficult to estimate treatment-related
risks for a particular patient because they vary tremen-
dously from one patient to the other, from one modality
to the other, and perhaps according to local expertise,
making clinical results published in the medical litera-
ture strongly dependent on case selection and compari-
sons between case series unreliable. What we can do
with the current non-randomized observational studies
is estimate the treatment risks and chances of success of
this sort of patient compared to this other sort of pa-
tients, but this reasoning should not make the treatment
of a patient justified any more than observation of the
other. If our experience and clinical intuition suggest
that individualized clinical decisions can be based on a
theoretical comparison between the supposed lifetime
risks of hemorrhage, and treatment-related risks (an un-
reliable process at best), the resulting singularized prac-
tice can never be validated as beneficial. In effect, acting
on an individual basis, examining the results after the
fact, can never tell us what would have happened had
the other management option been chosen. This ap-
proach blocks any subsequent attempts to demonstrate
the benefits of curative treatments for any group of pa-
tients. When a trial is finally proposed, the current clin-
ical culture foists upon us the idea that we are
sacrificing the care of individuals for the sake of gaining
scientific knowledge, and both patients and physicians
become reluctant to enroll [46, 47]. For a practice to be
validated as beneficial, we need similar patients that can
be managed by two management options, and we need
to show results that are better with one treatment than
the other, when they are randomly allocated.
The main differences between the present study and
the ARUBA trial are: a) a primary hypothesis in favor of
interventions; b) a harder primary endpoint; c) a longer
follow-up period; d) all inclusive selection criteria. The
hypothesis of the ARUBA trial was that conservative
management of unruptured AVMs was superior to
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interventional management. No evidence is necessary to
support the hypothesis that conservative management is
less risky in the short term. While the ARUBA results
are a reminder that by attempting preventive treatments
of brain AVMs we may be doing more harm than good,
should all attempts to cure unruptured brain AVMs now
be stopped? In fact, the burden of the proof was not on
neurologists who believed unruptured AVM patients
should be left alone; it has always been on the physicians
proposing those promising but risky preventive interven-
tions that have yet to be validated as beneficial. Unvalid-
ated risky preventive treatments should not be prescribed
just as validated care. The current context of brain AVM
therapy calls for a different approach.
Care trials have been designed to offer optimal care in
the presence of such uncertainty. If validated care can
simply be prescribed and acted upon, unvalidated care
can be offered, but only as a 50 % chance of receiving
the target intervention, and a 50 % chance of receiving
the validated alternative (or conservative management
when none exists), until the uncertainty is lifted and the
best management option identified. In this manner, well-
intended hypotheses, such as the one underlying all our
interventional practices that immediate risks are worth
taking to prevent poor outcomes from future ruptures,
can be transformed into better patient outcomes in real
life (when the hypothesis is verified), or harmful treat-
ments are abandoned before they do too much damage.
Once a treatment is validated (but not before), it can be
adopted as normal care. Self-disciplining our actions in
this manner would ensure continuous progress, not only
in knowledge about the disease or its treatment, but in
ever improving results of our clinical actions and out-
comes for our patients. If we understand this way of
controlling unvalidated risky preventive clinical inter-
ventions, we understand that proposing randomized al-
location of treatment options is not performed for the
sake of gaining knowledge. In this context it is the way
to offer optimal medical care, until the uncertainty is
lifted by the very trial being offered, and the best option
is identified.
We have chosen a relatively hard primary endpoint
(death and dependency) observed after a relatively long
follow-up period (10 years), because in most circum-
stances, physicians and patients are willing to accept
substantial risk to eradicate a lifetime AVM hemorrhage
risk. Furthermore, it is ill-advised to abandon curative
treatments due to transient or minor complications, es-
pecially when it is possible that the follow-up period has
been too short to identify the risks of conservative man-
agement. This means that a large number of patients
followed for a long period will be needed before defini-
tive conclusions can be drawn. In our view, this is ap-
propriate if we keep in mind the aim of the study. We
hope physicians already dedicating their professional
lives to offer highly specialized costly treatments for
these difficult patients will understand that although
everyone would like to have results as soon as possible,
more expedient studies using surrogate endpoints or
short follow-ups can only provide risky premature con-
clusions. Adjustments in trial design are needed, how-
ever, such as minimal intrusion in patient care, simple
CRFs that can be filled by care personnel, and no extra
test or cost, to ensure that results are not biased by the
necessity to control trial duration or expenses (when
conventional trials necessitate high monetary compensa-
tions) and that for the entire duration of the trial partici-
pation is meant to be optimal care in the presence of
uncertainty. Secondary endpoints were chosen to allow
the DSMC to monitor immediate treatment results and
ensure that harmful interventions are identified and
stopped as early as possible.
The same reasoning applies for the nested trial on pre-
surgical or pre-radiosurgical embolization. Although
many surgeons strongly believe embolization is helpful
in ensuring a safer and more complete surgical resection
in many cases, this benefit has never been proven. The
benefits in the operating room may end up being ne-
gated by the up-front risks of embolization. The same
considerations are involved in trying to improve the effi-
cacy of radiosurgery for AVMs that are considered too
large to be treated by this treatment modality.
None of the AVM treatment options have been vali-
dated so far, for any group of patients. This is to justify
the all-inclusive study design. It is possible to propose
random allocation even to those patients with ruptured
AVMs when risks of treatment are felt to be high (per-
haps as high as risks of not treating them), or when
complete eradication may be difficult. On the other hand
we understand that some beliefs are so entrenched that
they may have become impossible to question [46]. This
is the rationale for including the registry. For some pa-
tients with unruptured AVMs that are felt, by some col-
laborators, to be so safely curable that treatment is
considered mandatory; they can be part of the registry.
For example, if surgical resection of SM grade I patients
is shown to be very safe in multiple centers (say with
M&M less than 5 %, with narrow confidence intervals),
perhaps this treatment modality may be justified without
randomized evidence for that subgroup of patients. The
registry will also permit the identification of the patients
who were treated outside the randomized part of the
trial, and help in the interpretation of the generalizability
of trial results, a common concern with previous trials
in the neurovascular field [47]. The registry is also meant
to encourage the recruitment of as many expert centers
as possible, so that all can collaborate in trying to offer
optimal care for this difficult medical condition. We
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hope to convince all participants that randomized alloca-
tion is best for each individual, but it may take much
more time before this notion becomes widely accepted
by the clinical community. Although the registry data
may be difficult to interpret, it may provide valuable
insight into the various treatment modalities, particularly
for ruptured AVM patients. The current practices where
AVMs are treated on a case-by-case basis leave much to
be desired. Patients are better served by being treated
within a care research context, where, instead of having
a 100 % chance of being allocated an unvalidated inva-
sive treatment, they are offered a 50 % chance of getting
a potentially beneficial treatment, and an equal 50 %
chance of escaping the risks of a potentially deleterious
intervention. In the spirit of care trials, the protection of
current patients must always be given first consideration.
We thus accept that scientific hypotheses and the num-
ber of patients required to show significant differences
may need to be modified as the trial progresses.
Finally, although TOBAS was designed to include all
patients, it cannot serve to answer all questions. For ex-
ample, it was not conceived to provide valid compari-
sons between interventions, for patients eligible for two
or three various interventional options (surgery versus
radiosurgery; surgery versus embolization; embolization
versus radiosurgery).
Treatment of brain AVMs has never been validated as
beneficial. In the presence of such uncertainty, optimal
care has to be provided in a special context combining
research and care. TOBAS provides such a care trial
context to help the collaborative efforts of multiple ex-
pert centers in providing optimal management of pa-
tients with brain AVMs immediately and eventually to
lift some of the uncertainty regarding best management
options.
Trial status
TOBAS is currently recruiting patients in one Canadian
center, and the protocol is under ethics board review at
other national and international sites. To date, 80 pa-
tients have been recruited.
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